TGen Clinical Research Services at Scottsdale Healthcare is first to test new drug by Italian firm

December 08, 2009

SCOTTSDALE, Ariz. -- Dec. 8, 2009 -- TGen Clinical Research Services at Scottsdale Healthcare (TCRS) is the world's first clinical trials site for a new drug designed to halt cancer cell division.

NMS-1286937 is produced by Nerviano Medical Sciences of Milan, Italy's largest pharmaceutical research and development facility. NMS-1286937 is designed to stop cancer from spreading by preventing mitosis, the process of cell division.

"Cancer is driven by abnormal cell division and growth. Striking cancer cells at a key mechanism for growth opens up new possibilities, especially for lung and head and neck cancer patients," said Dr. Glen J. Weiss, Director of Thoracic Oncology at TCRS.

TCRS is a partnership between the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare that enables laboratory discoveries to be quickly turned into targeted therapies that can be tested with patients at the Virginia G. Piper Cancer Center in Scottsdale.

This Phase 1 clinical trial of as many as 40 adults with solid tumors will help determine if NMS-1286937 is safe and effective, and should lead to further clinical assessment.

Dr. Daniel Von Hoff - TGen's Physician-In-Chief, Chief Scientific Officer at TCRS and principal investigator for the trial - described NMS-1286937 as a potent and selective polo-like kinase 1 inhibitor designed to stop cancer cells from dividing by targeting the process of mitosis. High expression of polo-like kinase 1 is present in a wide range of cancers, including lung, colorectal, breast, pancreatic, head, neck, thyroid and ovarian cancer.

NMS-1286937 will be administered orally. Preclinical studies demonstrated that NMS-1286937 is effective against even aggressive cancers known to be resistant to the current standard of care.

"We at Nerviano are excited about the prospects of this new drug and are pleased to be partnering in this endeavor with TGen and Scottsdale Healthcare,'' said Maria Adele Pacciarini, Clinical Programme Director in Clinical Oncology at Nerviano Medical Sciences.
-end-
For more information about clinical trials and eligibility, contact TCRS's patient care coordinator Joyce Ingold, R.N., at 480-323-1339, toll free at 1-877-273-3713 or at clinicaltrials@shc.org.



About the Virginia G. Piper Cancer Center at Scottsdale Healthcare

The Virginia G. Piper Cancer Center at Scottsdale Healthcare offers diagnosis, treatment, research, prevention and support in its facilities at the Scottsdale Healthcare Shea Medical Center, attracting patients from across Arizona and the U.S. Groundbreaking cancer research is conducted through its Scottsdale Clinical Research Institute and TGen Clinical Research Service. Scottsdale Healthcare is the not-for-profit parent organization of the Scottsdale Healthcare Shea Medical Center, Scottsdale Healthcare Osborn Medical Center and Scottsdale Healthcare Thompson Peak Hospital, Virginia G. Piper Cancer Center, Scottsdale Clinical Research Institute and Scottsdale Healthcare Foundation. For additional information, please visit www.shc.org.

Press Contact:

Keith Jones, Director of Public Relations
Virginia G. Piper Cancer Center at Scottsdale Healthcare
480-882-4412
kjones@shc.org



About TGen

The Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. TGen is affiliated with the Van Andel Research Institute in Grand Rapids, Michigan. For more information, please visit: www.tgen.org.

Press Contact:

Steve Yozwiak
TGen Senior Science Writer
602-343-8704
syozwiak@tgen.org



About Nerviano Medical Sciences
Nerviano Medical Sciences is the largest pharmaceutical research and development facility in Italy, and one of the largest oncology-focused, integrated discovery and development companies in Europe. NMS was spun off from Pfizer in May 2004. Since then, NMS Oncology has brought into clinical trials 3 first in class NCEs. NMS Oncology has more than 20 targeted drugs in preclinical phase, along with 5 innovative cancer drugs in Phase I and Phase II clinical studies in cancer. In the last three years, NMS Oncology has successfully generated 2 high quality anti-cancer clinical candidates every year. For more information, please visit: www.nervianoms.com/cont/en/home-page/0705/2500/home-page.asp.

The Translational Genomics Research Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.